Comments
GlaxoSmithKline Plc Chairman Philip Hampton will step down after more than three and a half years in the role, Britain's biggest drugmaker announced on Monday.
The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products.
Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 per cent-owned by the British company, in an all-equity transaction.
“Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years,” Hampton said in a statement.
Before joining GSK, Hampton was chairman of Royal Bank of Scotland Group Plc and J Sainsbury plc. GSK, which is looking to buy early-stage assets and partner with companies, said it had started the search for a successor.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.